RxSight, Inc.
RXST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $140 | $89 | $49 | $23 |
| % Growth | 57.1% | 81.8% | 116.9% | – |
| Cost of Goods Sold | $41 | $35 | $28 | $18 |
| Gross Profit | $99 | $54 | $21 | $5 |
| % Margin | 70.7% | 60.4% | 43.5% | 20% |
| R&D Expenses | $34 | $29 | $26 | $24 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $101 | $75 | $59 | $33 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $136 | $104 | $85 | $57 |
| Operating Income | -$37 | -$50 | -$63 | -$53 |
| % Margin | -26.3% | -56.2% | -129.2% | -233.6% |
| Other Income/Exp. Net | $9 | $1 | -$3 | $4 |
| Pre-Tax Income | -$27 | -$49 | -$67 | -$49 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$27 | -$49 | -$67 | -$49 |
| % Margin | -19.6% | -54.6% | -136.2% | -215.5% |
| EPS | -0.71 | -1.41 | -2.41 | -1.78 |
| % Growth | 49.6% | 41.5% | -35.4% | – |
| EPS Diluted | -0.71 | -1.41 | -2.41 | -1.78 |
| Weighted Avg Shares Out | 39 | 34 | 28 | 27 |
| Weighted Avg Shares Out Dil | 39 | 34 | 28 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $7 | $2 | $0 |
| Interest Expense | $0 | $3 | $5 | $4 |
| Depreciation & Amortization | $4 | $4 | $4 | $4 |
| EBITDA | -$24 | -$41 | -$58 | -$41 |
| % Margin | -17% | -46.1% | -117.9% | -181.5% |